AIM: To study the role of @entity12 ( @entity12 ) and @entity522 expression in @entity105 and progression of @entity356 and molecular mechanisms of relevant immune escape. METHODS: @entity12 and @entity522 expression was studied in adjacent epithelial cells, @entity5 cells and lymphocytes of primary foci, and @entity5 cells of metastatic foci from 113 cases of @entity356 by streptavidin- @entity1885 -peroxidase (S-P) immunohistochemistry. Expression of both proteins in @entity5 cells of primary foci was compared with clinicopathological features of @entity356 . The relationship between @entity12 expression in @entity5 cells and @entity522 expression in @entity5 cells or infiltrating lymphocytes of primary foci was investigated. RESULTS: @entity5 cells of primary foci expressed @entity12 in 53.98 % (61/113) of @entity356 , more than their adjacent epithelial cells (34.51 %, 39/113) (P=0.003, chi(2)=8.681), while the expression of @entity522 in @entity5 cells of primary foci was detected in 32.74 % (37/113) of @entity356 , less than in the adjacent epithelial cells (50.44 %, 57/113) (P=0.007, chi(2)=7.286). Infiltrating lymphocytes of the primary foci showed positive immunoreactivity to @entity522 in 70.80 % (80/113) of @entity356 , more than their corresponding adjacent epithelial cells (P=0.001, chi(2)=10.635) or @entity5 cells of primary foci (P=0.000, chi(2)=32.767). @entity12 was less expressed in @entity5 cells of metastases (51.16 %, 22/43) than in those of the corresponding primary foci (81.58 %, 31/38) (P=0.003, chi(2)=9.907). Conversely, @entity522 was more expressed in @entity5 cells of metastases (58.14 %, 25/43) than in those of the corresponding primary foci (34.21 %, 13/38) (P=0.031, chi(2)=4.638). @entity12 expression was significantly correlated with @entity5 size (P=0.035,rs=0.276), invasive depth (P=0.039, rs=0.195), @entity3 (P=0.039, rs=0.195), differentiation (P=0.015, rs=0.228) and Lauren's classification (P=0.038, rs=0.196), but not with age or gender of @entity1 , growth pattern or TNM staging of @entity356 (P>0.05). In contrast, @entity522 expression showed no correlation with any clinicopathological parameters described above in @entity5 cells of the primary foci (P>0.05). Interestingly, @entity12 expression in primary @entity356 cells paralleled to @entity522 expression in infiltrating lymphocytes of the primary foci (P=0.016, chi(2)=5.825). CONCLUSION: Up-regulated expression of @entity12 and down-regulated expression of @entity522 in @entity5 cells of primary foci play an important role in @entity356 . As an effective marker to reveal the biological behaviors, @entity12 is implicated in differentiation, growth, invasion and @entity3 of @entity356 by inducing apoptosis of infiltrating lymphocytes. Chemical substances derived from the primary foci and metastatic microenvironment can inhibit the growth of metastatic cells by enhancing @entity522 expression and diminishing @entity12 expression.

Expression of @entity12 and XXXX contributes to formation of immune escape in @entity356 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity522 :: ('836', 'Gene') :: ['Caspase-3'] @entity1885 :: ('MESH:D001710', 'Chemical') :: ['biotin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Cancer'] @entity12 :: ('356', 'Gene') :: ['FasL', 'Fas ligand'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric cancers', 'gastric carcinogenesis']
@entity522 :: (836,Gene) :: ['caspase-3']
